Latanest (Latanoprost)

Latanoprost activates FP receptors in the eye’s ciliary body, remodeling the extracellular matrix of the uveoscleral outflow pathway. This increases drainage of aqueous humor, thereby reducing intra‑ocular pressure.

The dosing regimen for Latanest is determined by the prescribing clinician based on the patient’s condition and response. Typically, one drop is instilled in the affected eye(s) once daily in the evening, but exact instructions must come from a qualified eye‑care professional.

Safety data for latanoprost in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the prescriber in consultation with the patient.

To request Latanest, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanest (latanoprost) is a prostaglandin analog, generally considered first‑line therapy because of its once‑daily dosing and strong IOP‑lowering effect. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, it often provides greater pressure reduction with a favorable dosing schedule, though individual response may vary.

Latanest should be stored at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from light and moisture, and discard any solution that appears discolored or contaminated.

Latanest is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place a single drop into the conjunctival sac of the prescribed eye(s). Avoid touching the tip of the bottle to the eye or any surface.

Serious risks include severe ocular inflammation such as uveitis or iritis, allergic reactions affecting the eyelids or conjunctiva, and rare cases of sudden vision loss. Patients should report any intense eye pain, redness, swelling, or visual changes to their eye‑care provider promptly.

Latanest is contraindicated in patients with known hypersensitivity to latanoprost or any component of the formulation, and it should be used with caution in individuals with active ocular infections, recent ocular surgery, or a history of herpetic eye disease.